Maternal and Child Health Hospital of Hainan Province, No. 15, Long Kun Nan Road, Haikou, 570206, Hainan, China.
Med Oncol. 2013;30(3):681. doi: 10.1007/s12032-013-0681-x. Epub 2013 Aug 7.
MicroRNA-203 (miR-203), possessing tumor suppressive or promotive activities, has been found to be downregulated or upregulated in different cancer types. The purpose of this study was to investigate whether the increased expression of miR-203 can be used as a noninvasive diagnostic and prognostic biomarker in epithelial ovarian cancer (EOC). Real-time quantitative PCR was performed to detect the expression levels of miR-203 in EOC tissues. The expression levels of miR-203 were significantly higher in EOC tissues compared to adjacent non-cancerous tissues (p < 0.001). High expression of miR-203 was observed in 65.38 % (102/156) of EOC. In addition, high miR-203 expression was found to be closely correlated with advanced FIGO stage (p < 0.001), higher histological grade (p = 0.02), lymph node involvement (p < 0.001), and positive recurrence (p < 0.001). Moreover, high miR-203 expression was correlated with shorter overall survival (p < 0.001) and shorter progression-free survival (p < 0.001) of EOC patients. Furthermore, multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC. These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients.
微小 RNA-203(miR-203)具有肿瘤抑制或促进作用,已在不同类型的癌症中发现下调或上调。本研究旨在探讨 miR-203 的高表达是否可作为上皮性卵巢癌(EOC)的非侵入性诊断和预后生物标志物。实时定量 PCR 用于检测 EOC 组织中 miR-203 的表达水平。EOC 组织中 miR-203 的表达水平明显高于相邻非癌组织(p<0.001)。miR-203 的高表达见于 65.38%(102/156)的 EOC 患者。此外,高 miR-203 表达与 FIGO 晚期(p<0.001)、组织学分级较高(p=0.02)、淋巴结受累(p<0.001)和阳性复发(p<0.001)密切相关。此外,高 miR-203 表达与 EOC 患者的总生存期(p<0.001)和无进展生存期(p<0.001)较短相关。此外,多因素分析显示 miR-203 表达状态是 EOC 患者总生存期和无进展生存期的独立预测因素。这些发现首次提供了令人信服的证据,表明 miR-203 的上调可能作为一种新的分子标志物,预测 EOC 患者侵袭性肿瘤进展和不良预后。